| |
Training set |
Test set |
| TCEs |
7,263 |
375 |
| Mean (median) baseline VL (log10 c/mL) |
4.20 (4.11) |
4.34 (4.30) |
| Mean (median) baseline CD4(cells/μL) |
269 (230) |
277 (235) |
| Treatment History |
|
|
| Mean (median) number of previous drugs |
5.82 (5) |
5.56 (5) |
| NRTI experience |
99% |
100% |
| NNRTI experience |
65% |
54% |
| PI experience |
75% |
79% |
| Enfuvirtide experience |
6% |
0% |
| Raltegravir experience |
1% |
1% |
| Mean (median) resistance mutations |
8.48 (6) |
8.34 (8) |
| Responders(<1.7log10 c/mLfollow-up VL) |
2,550 (35%) |
18 (5%) |
| Failures(≥1.7log10 c/mLfollow-up VL) |
4,713 (65%) |
357 (95%) |
TCEs=treatment change episodes. VL=viral load. NRTI=nucleoside reverse
transcriptase inhibitor. NNRT=non-nucleoside reverse transcriptase inhibitor.
PI=protease inhibitor |
